Stanford's SPARK hosts ideas so 'crazy' they just might work

Stanford University School of Medicine tells the tale of one researcher's desire to move her research into better heart disease drugs out of the lab and into the clinic--a quest that, she learned the hard way, turned out to be naive as doors were politely slammed in her face. So, Daria Mochly-Rosen decided to take matters into her own hands. And that was the spark for SPARK, Stanford's bioscience incubator, founded 5 years ago to nurture "crazy ideas" that pharmaceutical companies won't touch. Feature

Suggested Articles

Salk scientists identified genes that control the activity of key immune cells, which could inspire ideas for treating cancer and autoimmune diseases.

Vor Biopharma raised $110 million to move its lead program, an engineered stem cell treatment for acute myeloid leukemia, into the clinic.

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.